On 18 September 2026, inside Zhangjiang Science Hall, a government conference did something unusual for an emerging technology: it treated brain-computer interfaces (脑机接口) as a finished industry rather than a lab curiosity. The message from the stage was that the district was already building the cluster, not merely researching the technology.
Pudong, the Shanghai district that hosts most of the city's biotech and semiconductor capacity, is not new to the field. It calls itself one of the earliest parts of China to lay out brain science and brain-computer interface (BCI) industry. What changed this autumn is scale and intent: a published plan, a named cluster of companies, and a set of supporting institutions.
Key takeaways
- Pudong says it has already gathered 26 upstream and downstream BCI enterprises, forming a cluster that spans core technology and multiple applications.
- The district unveiled the Pudong New Area Action Plan for Cultivating a Brain-Computer Interface Future-Industry Pilot Zone at the 2026 Zhangjiang Pharmaceutical Valley Industry Innovation Conference.
- The plan sets four tasks, built on the principle of strengthening foundations, forging chains, building clusters, and driving use.
- Pudong will develop BCI along three tracks — medical rehabilitation, consumer health, and industrial intelligence — across a dual-core layout of Zhangjiang and Waigaoqiao.
What the plan actually does
The action plan is a forward-looking policy document covering 2026–2028, not a binding regulation with a fixed effective date. It had gone through public consultation before being presented at the September conference. Its job is to coordinate, not to legislate: it names the bodies that should act, the capabilities to build, and the scenarios to prioritize.
The four tasks are deliberately broad. The first pushes source innovation — high-level research platforms and breakthrough work on core devices, large-model (大模型) and encoding/decoding algorithms. The second strengthens the full chain, from animal testing and regulatory review to clinical research and data support, including a "1+N" clinical research service matrix and an ethics fast-track. The third builds the hard-tech industry cluster around the Zhangjiang–Waigaoqiao dual core. The fourth protects the sector with scenarios and standards, including a "standard-leading" campaign to help draft industry norms.
Two details matter for readers outside China. First, Pudong states it has already formulated and implemented what it describes as China's first local BCI standard and is drafting six national standards. Standards are the unglamorous infrastructure that lets hospitals, regulators, and buyers compare claims on the same vocabulary — exactly the kind of readiness that follows demos. Second, the district launched a biomedical translation fund and granted plaques to BCI clinical-diagnosis and rehabilitation demonstration bases, creating a "first-use" channel so new products can reach wards faster.
Why a district, not a company
Pudong's bet is structural. Rather than backing a single flagship implant, it is trying to make the whole pipeline cheaper to run: shared pilot plants, talent apartments, regulatory innovation, and financial support. The logic, in the district's framing, is that BCI's bottleneck has shifted from any single breakthrough to the cost and time of moving from animal study to clinic to reimbursement. Pudong is not alone in this approach; Beijing, Guangdong, and Tianjin have each announced their own BCI industrial priorities, but Pudong's combination of top clinical hospitals, semiconductor supply, and free-trade-zone policy tools is unusually complete.
At the conference, an expert advisory committee was announced with names including Hong Bo (洪波) of Tsinghua University and Mao Ying (毛颖) of Huashan Hospital affiliated with Fudan University. Their role is to advise on technical research (技术攻关), standard-setting, and strategy.
According to Li An, chief scientist at BrainNet (脑机网), China's BCI race is shifting from isolated clinical firsts toward clustered industrial capacity, and district-level ecosystems like Pudong's are where the next phase of commercialization will be decided.
What readers can do now
- If you track BCI commercially, watch Pudong's six national standards in progress — they will define what counts as a compliant device in China's largest healthcare market.
- For founders and clinicians, the "first-use" demonstration bases are the signal: products that clear them get a faster path into Shanghai wards.
- For global readers, treat "26 companies" as a floor, not a ceiling — the plan's explicit goal is to deepen the cluster, so expect more entrants and more M&A.
Honest limitations
This article draws on the Shanghai municipal government's English and Chinese news services, the Pudong government portal, and corroborating reports from Economic Daily (经济日报) and China Development Network. The central figures — 26 enterprises, four tasks, three tracks, dual-core layout, and the already-implemented first local BCI standard — are reported consistently across these official and state-media sources and are presented as stated. I have described the 2026–2028 action plan as a policy/guidance document that went through public consultation, not as a binding law with a fixed effective date; the distinction matters and I have not overstated its legal force. I have not independently audited the list of 26 firms or the six national standards' draft text, and I have not covered parallel BCI clusters in Beijing, Guangdong, or Tianjin in depth. The Li An remark is a qualitative trend reading, not a quantitative claim.